

July 23, 2021

CURRICULUM VITAE

NAME: WILLIAM MARTENS LEE

DATE OF BIRTH: January 30, 1942

PLACE OF BIRTH: New York, USA

MARITAL STATUS: Married: Elizabeth Maxwell, 1966
Children: Matthew
Edmund
Caroline

OFFICE ADDRESS: Division of Digestive and Liver Diseases
Department of Internal Medicine
University of Texas Southwestern Med School
5323 Harry Hines Blvd
Dallas, TX 75390-8887
(214) 645 6111
referrals/clinic (214) 645 8300
FAX (214) 645 6114
internet address: william.lee@utsouthwestern.edu

HOME ADDRESS: 3740 Holland Avenue 3D
Dallas TX 75219
214 443 1885
214 616 5313 cell

PRESENT APPOINTMENTS:

| | |
|--|--------------|
| Professor of Internal Medicine University of Texas Southwestern Medical School | 1990-present |
| Holder of the Meredith Mosle Chair in Liver Disease, in honor of William M. Lee, MD | 2003-present |
| Professor of Clinical Medicine The Ohio State University | 2010-2014 |

EDUCATION: Amherst College, BA cum laude 1963
 Columbia University
 College of Physicians & Surgeons, MD 1967, AOA

PREVIOUS APPOINTMENTS:

Director, Gastroenterology Division 1989-90
 Professor of Medicine
 Medical University of South Carolina

Interim Director, Gastroenterology Division
 Medical University of South Carolina 1987-88

Associate Professor of Medicine
 Medical University of South Carolina 1982-89

Assistant Professor of Medicine
 Medical University of South Carolina 1980-82

Assistant Professor of Clinical Medicine
 Columbia University
 College of Physicians and Surgeons 1976-80

Assistant Attending Physician
 Presbyterian Hospital, New York 1974-80

Associate in Clinical Medicine
 Columbia University College of
 Physicians and Surgeons 1974-76

Research Fellow and Honorary Registrar
 to Dr. Roger Williams
 Liver Unit
 Kings College Hospital Medical School
 London, England 1973-74

Chief Resident (Medicine)
 Presbyterian Hospital, New York 1972-73

Assistant Resident (Medicine)
 Presbyterian Hospital, New York 1970-72

Senior Assistant Surgeon
 St. Elizabeth's Hospital

U.S. Public Health Service
Washington, D.C. 1968-70

Internship (Medicine)
Presbyterian Hospital, New York 1967-68

HONORS AND
ORGANIZATIONS:

John Woodruff Simpson Fellow
Amherst College 1963

Alpha Omega Alpha
Columbia University 1966

American Board of Internal Medicine 1973

Eli Lilly Fellow
American College of Physicians 1973

American Association for the Study
of Liver Disease, Member/Fellow 1976, 2014

American College of Physicians, Member 1977

ABIM Gastroenterology Board 1978

American College of Physicians, Fellow 1979

American Gastroenterological
Association, Member, Fellow 1979, 2020

American Society for Gastrointestinal
Endoscopy, Member 1979-2014

Blaine Brower Traveling Scholar,
American College of Physicians 1980

Gastroenterology Research Group 1984-1994

American Federation for Clinical
Research 1985-1990

Thomas A. and Shirley W. Roe Award

| | |
|---|------|
| Journal of the SC Med Association | 1988 |
| American College of Gastroenterology, Fellow | 1989 |
| Leon Schiff Memorial Lecture AASLD Annual Meeting | 2008 |
| Hyman Zimmerman Memorial Lecture AASLD Annual Meeting | 2013 |
| AASLD Distinguished Clinician Educator/Mentor Award | 2014 |
| Columbia University Vagelos College of Physicians and Surgeons Alumni Gold Medal for Clinical Excellence | 2018 |

STANDING COMMITTEES:

| | |
|--|--------------------|
| Faculty Senate, MUSC | 1982-84 |
| Clinical Research Fellow Steering Committee, Chairman | 1982-87 |
| Department of Medicine House Staff Recruitment Committee, Chairman | 1983-89 |
| Steering Committee, Gastro Section, Southern Medical Association Chairman | 1983-90 1987-88 |
| Editorial Board, <i>J Clin Gastroenterology</i> | 1984-91 |
| Institutional Review Board, MUSC | 1986-87 |
| American Gastroenterological Association Training and Education Committee | 1986-89 |
| Board of Directors, Charleston Interfaith Crisis Ministry (Homeless Shelter) | 1986-90 |
| Director, South Carolina Medicaid | |

| | |
|---|--------------|
| Liver Transplantation Program | 1987-90 |
| Board of Directors, Interfaith Housing Coalition, Dallas | 1990-93 |
| American Ass'n for Study of Liver Disease Publications Committee | 1990-93 |
| Chairman, <i>Hepatology</i> subcommittee | 1994-1995 |
| Chairman, Publications Committee | 1995-97 |
| Board of Directors, Special Camps for Special Kids, Dallas | 1991-93 |
| Selected Summaries Contributor, <i>Gastroenterology</i> | 1992-7 |
| Medical Staff Executive Committee Zale-Lipshy University Hospital | 1992-94 |
| Board of Directors, Hope Cottage Adoption Agency | 1993-99 |
| Study Section: NIH Hepatitis C Cooperative Research Centers | 1996 |
| American Ass'n for Study of Liver Disease Secretary-Treasurer | 1997-2000 |
| Consultant Member, Food and Drug Administration Anti- Infective Advisory Committee | 2001-2007 |
| Member, FDA, PhRMA, AASLD ad hoc committee on nomenclature for drug hepatotoxicity | 2001-present |
| Consultant, Food and Drug Administration OTC Product Advisory Committee | 2002, 2009 |
| Consultant, White House Office Narcotic Drug Control Policy | 2004-2006 |
| Board of Directors, KERA Public Radio Station | 2010-16 |
| NIH Clinical Neuroimmunology and Brain Tumors Study Section | 2019 |

PUBLISHED WORKS:
PEER-REVIEWED PAPERS

1. Lee WM, Bragg II FE, Jaffe ER. Reduction of methemoglobin in human adult and cord blood erythrocytes incubated with glucose and inosine. *Proc Soc Exp Biol Med* 1967;124: 214-217
2. Reed WD, Eddleston ALWF, Mitchell CG, Lee WM, Zuckerman AJ, Williams R. Exposure and immunity to the hepatitis B virus in a liver unit. *Lancet* 1974 i, 581-585
3. Lee WM, Reed WD, Mitchell CG, Eddleston ALWF, Zuckerman AJ, Williams R. Cellular and humoral immunity to the hepatitis B antigen in active chronic hepatitis. *Br Med J* 1975;1: 705-708
4. Lee WM, Reed WD, Mitchell CG, Dymock IW, Woolf IL, Eddleston ALWF, Williams R. Cell-mediated immunity to hepatitis B antigen in blood donors with persistent antigenemia. *Gut* 1975;16: 4116-418
5. Woolf IL, Sheikh NE, Cullens H, Lee WM, Eddleston ALWF, Williams R, Zuckerman AJ. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. *Br Med J* 1976;2:669-671.
6. Lee WM, Mitchell CG, Reed WD, Vahrman J, Zuckerman AJ, Eddleston ALWF, Williams R. Immune responses to hepatitis B surface antigen and to liver-specific lipoprotein in acute type B hepatitis. *Gut* 1977;18:250-7
7. Shelton LL, Lee WM, Curtis GM, Arnaud P, Galbraith RM. Membrane antigens in chronic active hepatitis: physicochemical and immunological studies of soluble liver homogenate fractions. *Clin Immunol Immunopathol* 1983;28:135-141
8. Lee WM, Shelton LL, Galbraith RM. Antibodies to hepatocyte membrane antigens in chronic liver disease: detection by immuno-flourescence after Bouin's fixation. *J Histochem Cytochem* 1983;31:1246-49
9. Lee WM, Emerson DL, Werner PAM, Arnaud P, Goldschmidt-Clermont PJ, Galbraith RM. Decreased serum group-specific component protein levels and complexes with actin in fulminant hepatic necrosis. *Hepatology* 1985;5:271-275
10. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Werner PAM, Lee WM. Effects of ligand binding upon measurement of Gc by rocket immunoelectrophoresis: implications for protein determination and for studies of protein/ligand interactions. *Electrophoresis* 1985;6:155-61

11. Goldschmidt-Clermont PJ, Galbraith RM, Emerson EL, Werner PAM, Nel AE, Lee WM. Accurate quantitation of native Gc in serum and estimation of endogenous Gc:G-actin complexes by rocket immunoelectrophoresis. *Clin Chim Acta* 1985;148:173-183
12. Lee WM, Martin KL, Shelton LL, Galbraith RM. Hepatic membrane antibodies: studies of prevalence and specificity. *Clin Exp Immunol* 1985;62: 715-23
13. Lee WM, Holley HP, Galbraith GMP. Refractory esophageal candidiasis associated with a plasma inhibitor of T-lymphocyte function. *Am J Med Sci* 1986;292:47-52
14. Reynolds FS, Lee WM. Hepatotoxicity following long-term methotrexate. *Southern Med J* 1986;79:536-9
15. Mazzetti M, Stefanini GF, Mazzeo V, Baraldini M, Canonica GW, Marini E, Miglio F, Gasbarrini G, Lee WM. Alterations in helper-specific circulating T-lymphocytes and in the autologous mixed lymphocyte reaction (AMLR) in chronic hepatitis B. *Am J Gastro* 1987;82:130-4
16. Young WO, Goldschmidt-Clermont PJ, Emerson DL, Lee WM, Jollow DJ, Galbraith RM. Correlation between extent of liver damage in fulminant hepatic necrosis and complexing of circulating Gc (Vitamin D-binding protein). *J Lab Clin Med* 1987;110:83-90
17. Lee WM, McLeod L, Martin KL, Galbraith RM. Antibodies to polymerized human serum albumin in acute and chronic liver disease. *Hepatology* 1987;7: 906-912
18. Lee WM, Young WO, Goldschmidt-Clermont PJ, Jollow DJ, Emerson DL, Galbraith RM. Diminished serum Gc (Vitamin D-binding protein) levels and increased Gc:G-actin complexes in a hamster model of fulminant hepatic necrosis. *Hepatology* 1987;7:825-30
19. Goldschmidt-Clermont PJ, Lee WM, Galbraith RM. Proportion of Gc (Vitamin D-binding protein) in complexed form: relation to clinical outcome in fulminant hepatic necrosis. *Gastroenterology* 1988;94:1454-58
20. Lee WM, Reines HD, Watt GN, Cook JA, Halushka PV, Wise WC, Galbraith RM. Alterations in Gc protein levels and complexing in septic shock. *Circ Shock* 1989;28:249-55
21. Walpole HE, Lee WM, Walle T, Walle UK, Wilson MJ, Kennedy JW. Rabbit hepatocytes in primary culture: preparation, viability, and use in studies of propranolol metabolism. *Hepatology* 1990;11:394-400.

22. Wootton FT, Lee WM. Acetaminophen hepatotoxicity in the alcoholic. *Southern Med J* 1990;83:1047-1049.
23. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. *N Engl J Med* 1992;326:1335-41.
24. Lee WM, Iverson A, McLeod L, Walpole HE, Arnaud P, Cote PJ, Gerin JL, Tennant B. Antibodies to polymerized albumin in woodchuck hepatitis virus infection. *Viral Immunology* 1993;6:13-19.
25. Lee WM. Medical Progress: Acute liver failure. *N Engl J Med* 1993;329:1862-72.
26. Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA. Mooren-type hepatitis C virus-associated corneal ulceration. *Ophthalmology* 1994;101:736-45
27. Lee WM, Galbraith RM, Watt GH, Hughes RD, Hoffman BJ, Williams R. Predicting survival in fulminant hepatic failure using serum Gc protein concentrations. *Hepatology* 1995;21:101-5.
28. Lee WM. Medical Progress: Drug-Induced Hepatotoxicity. *N Engl J Med* 1995;333:1118-27
29. Karlsberg PL, Lee WM, Casey DL, Cockerell CJ, Cruz PD Jr. Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia. *Arch Dermatol* 1995;131:1119-23
30. Thiele DL, DuCharme L, Cunningham MR, Mimms LT, Cuthbert JA, Lee WM, Combes B. Steroid therapy of chronic hepatitis: Characteristics associated with response in anti-HCV positive and negative patients. *Am J Gastroenterol* 1996;91:300-08
31. Suhler E, Lin W, Yin H, Lee WM. Decreased plasma gelsolin levels in acute liver failure, myocardial infarction, septic shock and myonecrosis. *Crit Care Med* 1997;25:594-8
32. Wians FH Jr, Lin W, Brown LP, Schiødt FV, Lee WM. Immunonephelometric quantification of group-specific component protein in patients with acute liver failure. *Liver Transplant Surg* 1997;3:28-33
33. Schiødt FV, Rochling FJ, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. *N Engl J Med* 1997;337:1112-17.
34. Lee WM. Medical Progress: Hepatitis B virus infection. *N Engl J Med*, 1997;337:1733-45

35. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. *Hepatology* 1997;26:747-54
36. Hamid S, Cruz Jr PD, Lee WM. Urticarial vasculitis caused by hepatitis C virus infection: response to interferon-alfa therapy. *J Amer Acad Dermatol*, 1998;39:278-80
37. Lee WM, Reddy KR, Tong M, et al. Early HCV RNA results predict interferon treatment outcomes in chronic hepatitis C. *Hepatology* 1998;28:1411-15
38. Pockros PJ, Tong M, Lee WM, van Leeuwen DJ, Keefe EM, Bala K, et al. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. *J Viral Hepatitis* 1998;5:271-6
39. McHutchison JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med* 1998;338:1485-92
40. Schiødt FV, Atillasoy E, Shakil O, Lee WM, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. *Liver Transplant Surg*, 1999;5:29-34.
41. Dahl B, Schiødt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. *Shock* 1999;12:102-04
42. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. *Hepatology* 1999;30:787-793.
43. Erukhimov JA, Tang Z-L, Johnson BA, Donahoe MP, Razzack JA, Gibson KF, Lee WM, Wasserloos KJ, Watkins SA, Pitt BR. Actin-containing sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. *Am J Resp Crit Care Med* 2000;162:288-94.
44. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP III, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Efficacy and safety of pegylated (40kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. *Hepatology* 2001; 33: 433-438.

45. Teo EK, Ostapowicz GA, Hussain M, Lee WM, Fontana RJ, Lok ASF and US ALF Study Group. Hepatitis B infection in patients with acute liver failure in the United States. *Hepatology* 2001; 33:972-76
46. Malik AH, Kumar KS, Malet PF, Ostapowicz G, Adams G, Wood M, Yarbrough K, Jones A, Lee WM. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon. *Aliment Pharmacol Ther* 2002;16:381-6.
47. Schiødt FV, Lee WM, Bondesen S, Ott P, Christensen E. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. *Aliment Pharmacol Ther* 2002;16:707-715.
48. McHutchison JG, Manns MP, Patel K, Poynard T, Lindsay KL, Christian Trepo C, Dienstag J, Lee WM, et al. Adherence to combination therapy enhances sustained response in patients with chronic hepatitis C infection. *Gastroenterology* 2002;123:1061-69.
49. Ostapowicz GA, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SBH, Lee WM, et al., Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med* 2002;137:945-54.
50. Dahl B, Schiødt FV, Ott P, Wians F, Lee WM, Balko J, O'Keefe GE. Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. *Crit Care Med* 2003;31:152-55.
51. Schiødt FV, Davern TJ, Shakil OA, McGuire B, Samuel G, Lee WM. Viral hepatitis-related acute liver failure. *Am J Gastroenterol* 2003;98:448-453.
52. Schiødt FV, Balko J, Schilsky MC, Harrison EH, Thornton A, Lee WM and the ALFSG. Thrombopoietin in acute liver failure. *Hepatology* 2003;37:558-61.
53. Lee WM. Medical Progress: Drug-Induced Hepatotoxicity. *N Engl J Med* 2003;349:474-85.
54. Umemura T, Tanaka E, Ostapowicz G, Lee WM, Heringlake S, Manns MP, Tassopoulos NC, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, aplastic anemia and acute and chronic non-A-E hepatitis. *J Inf Dis* 2003;188:1545-52.
55. Vaquero J, Polson J, Chung C, Helenowski I, Schiødt FV, Reisch J, Lee WM, Blei AT and the Acute Liver Failure Study Group. Infection and the progression to deep hepatic encephalopathy in early fulminant hepatic failure. *Gastroenterology* 2003; 125:755-764.

56. Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, Horton JW, Yin HL, Turnage RH. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. *J Appl Physiol* 2004; 96: 25 - 31.
57. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al., Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. *Gastroenterology* 2004;126:81-90.
58. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TM, Bonkovsky HL, Lee WM, Diengstag JL, Ghany MG, Goodman AD, Everhart JE and the HALT-C Trial Group Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed previous treatment. *Gastroenterology* 2004;126:1015-23.
59. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al., Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. *Contr Clin Trials* 2004;25:472-92.
60. Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, Davern TJ, Lee WM, Lok AS-F, and the Acute Liver Failure Group. Clinical outcome and virological characteristics of hepatitis B related acute liver failure in the United States. *J Viral Hep* 2005;12:192-8.
61. Polson J, Lee WM. AASLD Position Paper: Acute Liver Failure. *Hepatology* 2005;41:1179-97.
62. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, Sheth S. Hepatic findings in long-term clinical trials of ximelagatran. *Drug Safety* 2005; 28:351-70.
63. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR and The HALT-C Trial Group. Comparison of amplification enzymes for hepatitis C virus quasispecies analysis. *Virology* 2005;2:41-6.
64. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. *Hepatology* 2005;42:282-92.
65. Lee WM, Polson JE, Carney DS, Sahin B, Gale M, Jr. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: Evidence for an occult viral reservoir. *J Infect Dis* 2005;192:1088-92.

66. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM and the HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. *J Hepatology* 2005;43:434-41.
67. Schiodt FV, Rossaro L, Stravitz RT, Shakil OA, Chung RT, Lee WM, and the ALF Study Group. Gc-globulin and prognosis in acute liver failure. *Liver Transplant* 2005;11:1223-27.
68. Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, Han S, Harrison ME, Stravitz TR, Muñoz S, Brown R, Lee WM, Blei AT. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. *Liver Transpl* 2005;11:1581-9.
69. Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. *Dig Dis Sci* 2005;50:1785-90.
70. Larson AM, Fontana RJ, Davern TJ, Polson J, Lalani EK, Hynan LS, Reisch JS, Shakil OA, Schiødt FV, Ostapowicz GA, Lee WM and the ALFSG. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. *Hepatology* 2005;42:1367-72.
71. Davern II, TJ, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, Lalani EK, Munoz S, Shakil AO, Lee WM and the ALFSG. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. *Gastroenterology* 2006;130:687-94.
72. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, DiBisceglie AM, Lee WM, Dienstag HL, Ghany MG, Gretch DR and the HALTC Trial Group. HCV RNA detection by TMA during the hepatitis C antiviral longterm treatment against cirrhosis (HALT-C) trial. *Hepatology* 2006;44:360-67.
73. James LP, Alonso EM, Hynan LS, Hinson JA, Davern TJ, Lee WM, Squires RH and the Pediatric Acute Liver Failure Study Group. Detection of acetaminophen-protein adducts in children with acute liver failure of indeterminate cause. *Pediatrics* 2006;118:676-681.
74. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, and the HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial. *Hepatology* 2006;44:1675-84.

75. Schiodt FV, Ostapowicz GA, Murray N, Satyanarana R, Zaman A, Munoz S, Lee WM and the Acute Liver Failure Study Group. Alpha fetoprotein and prognosis in acute liver failure. *Liver Transpl* 2006;12:1776-81.
76. Rutherford A, Davern T, Hay JE, Murray NG, Hassanein T, Lee WM, Chung RT. High body mass index predicts poor outcome in acute liver failure. *Clin Gastroenterol Hepatol* 2006;4:1544-49.
77. Lee WM, Brown KE, Young NS, Dawson GJ, Schlauder GG, Gutierrez RA, Fontana R, Rossaro L, Davern T, Lalani E and the Acute Liver Failure Study Group. Brief Report: No evidence for hepatitis E or parvovirus B19 Infection in patients with acute liver failure. *Dig Dis Sci* 2006 51:1712-5.
78. Jain MK, Parekh NK, Hester J, Lee WM. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. *AIDS Patient Care STDS*. 2006;20:817-822.
79. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR; HALT-C Trial Group. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. *Hepatology*. 2006;44:360-7.
80. Schappert J, Wians FH Jr, Schiff E, Smalley D, Gambardella R, Lee WM, Wu J, Keiser P, Peterson D, De Medina M, Baker L, Preisel-Simmons B. Multicenter evaluation of the Bayer ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay. *Clin Chim Acta*. 2006;372:158-66.
81. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial. *Hepatology* 2006;44(:1675-84.
82. Averill J, Lee WM, Karandikar N. Differential dysfunction in dendritic cell subsets during chronic hepatitis C infection. *Clin Immunol* 2007;123:40-49.
83. Taylor RM, Davern TJ, Munoz S, Han SH, McGuire B, Larson AM, Hynan L, Lee WM, Fontana RJ and the ALFSG. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. *Hepatology* 2006;44:1589-97.
84. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DTY,

- Weinman SA, Lemon SM, Gale M. Viral and therapeutic control of IFN- β promoter stimulator 1 during hepatitis C virus infection. *PNAS* 2006;103: 6001-15.
85. Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV co-infected patients: factors associated with response. *J Viral Hep* 2007;14:176-82.
86. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR and the HALTC Trial Group. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. *Gastroenterology* 2007;132:103-11
87. Lok ASF, Everhart JS, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM and the HALTC Trial Group. Hepatic steatosis in hepatitis C: Comparison of diabetic and nondiabetic patients in the HALTC Trial. *Gastroenterol Hepatol* 2007;5:245-54
88. Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. Do HIV care providers appropriately manage hepatitis B in co-infected patients treated with anti-retroviral therapy? *Clin Infect Dis* 2007 2007;44:996-1000
89. Parekh NK, Hynan LS, De Lemos J, Lee WM and the ALF Study Group. Elevated troponin I levels in acute liver failure: Is myocardial injury an integral part of the acute liver failure? *Hepatology* 2007;45:1489-95
90. Stravitz RT, Kramer AH, Davern T, Shaikh AOS, Caldwell SH, Mehta RL, Blei AT, Fontana RJ, McGuire BM, Lee WM and the Acute Liver Failure Study Group. Intensive care of patients with acute liver failure: Recommendations of the Acute Liver Failure Study Group. *Crit Care Med* 2007;35:2498-2508
91. Schiodt FV, Bangert K, Shakil AO, McCashland T, Murray N, Hay JE, Lee WM and the Acute Liver Failure Study Group. Predictive value of actin-free Gc globulin in acute liver failure. *Liver Transplant* 2007;13:1324-29
92. Leung PSC, Davis PA, Park O, Miyakawa H, Norman G, Rossaro L, Lee WM, Gershwin ME and the Acute Liver Failure Study Group. Anti-mitochondrial autoantibodies in acute liver failure. *Hepatology* 2007;46:1436-42
93. Møller HJ, Grønbaek H, Schiødt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM and the ALFSG. Soluble CD 163 from macrophages predicts mortality in acute liver failure. *J Hepatol* 2007;47:671-6

94. Pillai V, Lee WM, Thiele D, Karandikar N. Clinical responders to interferon treatment for chronic hepatitis C show CD4+ and CD8+ responses. *J Viral Hep* 2007;14:318-29
95. Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, Vardhini K, Lee WM. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. *HIV Med* 2007;8:491-7
96. Rutherford AE, Hynan LS, Borges CBS, Forcione DG, Blackard JT, Lin W, Gorman AJ, Shaikh OS, Reuben A, Harrison E, Reddy KR, Lee WM, Chung RT. Serum apoptosis markers in acute liver failure: A pilot study. *Clin Gastroenterol Hepatol* 2007;5:1477-83
97. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG; HALT-C Trial Group. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. *Hepatology*. 2008;47:605-12
98. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute Liver Failure: Summary of a Workshop. *Hepatology* 2008;47:1401-15
99. Polson J, Wians Jr FH, Orsulak P, Fuller D, Murray NG, Koff JM, Khan AI, Balko JA, Hynan LS, Lee WM and the ALFSG. False positive acetaminophen concentrations in patients with liver injury. *Clin Chim Acta* 2008;391:24-30
100. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JL, Wright EC, Lee WM, et al. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon: the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial. *New Engl J Med* 2008;359:2429-41
101. Levitsky J, Thadareddy A, Lakeman FD, Whitley RJ, Luby JP, Lee WM, Fontana RJ, Blei AT, Ison MG. Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. *Liver Transplant* 2008;14:1498-1504.
102. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr, Lee WM, Schilsky M. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. *Hepatology* 2008;48:1167-74.
103. Lewis JH, Larrey D, Olsson R, Lee WM, Frison L, Keisu M. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. *Int J Clin Pharmacol Ther* 2008;46:327-39.
104. Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O'Brien TR, and the HALT-C Trial

- Group. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. *J Hepatology* 2008;49:548-56
105. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok ASF, Bonkovsky HL, Lee WM et al. Blunted cytopenias and weight loss: New correlates of virologic null response to re-treatment of chronic hepatitis C. *Clin Gastro Hepatol* 2008;6:234-41
 106. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok ASF, Dienstag JL, Ghany MG, Curto TM, and the HALT-C Trial Group. Interpretation of positive TMA test results from PCR-negative samples obtained after treatment of chronic hepatitis C. *Hepatology* 2008;
 107. Schiff E, Simsek H, Lee WM, Chao, Y-C, Sette H, Janssen HL et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. *Am J Gastroenterol* 2008;103:2776-83
 108. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM and Seeff L. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. *Hepatology* 2009;49:250-57
 109. Lok ASF, Seeff LB, Morgan TR, DiBisceglie AM, Sterling RK, Curto TM, Lindsay KM, Lee WM. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology* 2009;136:138-148
 110. Cote GC, Gottstein JH, Daud A, Lee WM, Blei AT and the ALFSG. The Role of etiology in the hyperamylasemia of acute liver failure. *Am J Gastroenterol* 2009;104:592-97
 111. James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee WM. Pharmacokinetics of acetaminophen protein adducts in adults with acetaminophen overdose and acute liver failure. *Drug Metab Dispos* 2009;37:1-6
 112. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TL III, Murray NG, McCashland T, Reisch J, Robuck PR and the ALFSG. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. *Gastroenterology* 2009; 137:856-864
 113. McHutchinson JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, et al. Peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for the treatment of chronic hepatitis C genotype 1 infection. *N Engl J Med* 2009;369:580-593

114. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. *Hepatology*. 2009;49:1847-58
115. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. *Hepatology* 2009;50:1360-9
116. Lok ASF, Everhart JE, Chung RT, Kim H-Y, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM and the HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the HALT-C Trial. *Hepatology* 2009;49:1828-37
117. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F et al. Merimepodib, pegylated interferon, and ribavirin in genotype-1 chronic hepatitis C pegylated interferon and ribavirin non-responders: a randomized study. *Hepatology* 2009;50:1719-26
118. Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M, Lee WM. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. *J Infect Dis* 2009;200: 866-76
119. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med* 2009;361:580-93
120. Forde KA, Reddy KR, Troxel AB, Sanders CM, Lee WM; Acute Liver Failure Study Group. Racial and ethnic differences in presentation, etiology, and outcomes of acute liver failure in the United States. *Clin Gastroenterol Hepatol* 2009;7:1121-6
121. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. *Gastroenterology* 2010;138:498-502
122. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright

- EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. *Gastroenterology* 2009;137:1986-94
123. Schiødt FV, Chung RT, Schilsky ML, Hay JE, Christensen E, Lee WM and the Acute Liver Failure Study Group. Outcome of acute liver failure in the elderly. *Liver Transpl* 2009 15:1481-7
124. Yuan HJ, Jain MK, Snow KK, Gale Jr, M, Lee WM and the HALT-C Trial Group. Evolution of hepatitis C virus NS5A region in breakthrough patients during interferon and ribavirin therapy. *J Viral Hep* 2010;17:208-216
125. Ghany MG, Lok ASF, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL and the HALT-C Trial Group. Predicting clinical and histological outcomes based on standard laboratory tests in advanced chronic hepatitis C. *Gastroenterology* 2010;138:136-46
126. Getachew Y, James L, Lee WM, Thiele DL, Miller BC. Biochem Pharmacol. Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. *Biochem Pharmacol* 2010; 79:1363-71
127. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. *Gastroenterol* 2010;138:136-46.
128. Li J, Zhu X, Liu F, Cai P, Sanders C, Lee WM, Uetrecht J. Cytokine and autoantibody patterns in acute liver failure. *J Immunotoxicol* 2010;7:157-164
129. Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ 2nd, Hayashi P, Lee WM, Seeff LB. Hepatotoxicity Due to Hydroxycut: A Case Series. *Am J Gastroenterol* 2010;105:1561-6
130. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al., Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C Trial. *Clin Gastroenterol Hepatol* 2010;8:977-83
131. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, Freston JW. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. *Drug Safety* 2010;33:503-22
132. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS.

- HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. *Hepatology* 2010;52:833-44
133. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE et al. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. *Gastroenterology* 2010; 138:2321-32
134. Seremba E, Ocama P, Opio CK, Kagimu M, Yuan HJ, Attar N, Thomas DL, Lee WM. Validity of rapid strip assay test (RSA) for detecting HBsAg among hospitalized patients in Uganda. *J Med Virol* 2010;82:1334-40
135. Li J, Zhu X, Liu F, Cai P, Sanders C, Lee WM, Uetrecht J. [Cytokine and autoantibody patterns in acute liver failure](#). *J Immunotoxicol* 2010;7:157-64.
136. Seremba E, Ocama P, Opio CK, Kagimu M, Thomas DL, Yuan HJ, Attar N, Lee WM. Poor performance of hepatitis C antibody tests in hospitalized individuals in Uganda. *J Med Virol* 2010; 82:1371-78
137. Gregory B, Larson AM, Reisch J, Lee WM. Acetaminophen dose does not predict outcome in acetaminophen-induced acute liver failure. *J Invest Med* 2010;58:707-10
138. Reuben A, Koch DG, Lee WM and the Acute Liver Failure Study Group. Drug-Induced Acute Liver Failure: Results of a United States multicenter, prospective study. *Hepatology* 2010;52:2065-78.
139. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG. IDEAL Study Team. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. *Gastroenterology* 2010;139:1602-11.
140. Hu KQ, Schiff ER, Kowdley KV, Min AD, Shiffman ML, Lee WM, Goodman ZD, Dau LO, Peschell KJ, Fagan EA, Flaherty JF. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. *J Clin Gastroenterol* 2010;44:510-6.
141. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology* 2010;139:120-9.

142. Strnad P, Zhou Q, Hanada S, Lazzeroni LC, Hui B, Zhong P, So P, Davern TJ, Lee WM for the Acute Liver Failure Study Group and Omary MB. Ethnic-specific keratin variants predispose to an adverse outcome in acute liver failure. *Gastroenterology* 2010;139:828-35.
143. Mohutsky MA, Romeike A, Meador V, Lee WM, Fowler J, Francke-Carroll S. Hepatic drug metabolizing enzyme induction and implications for preclinical and clinical risk assessment. *Toxicol Pathol* 2010;38:799-809.
144. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. *Hepatology* 2011;54:396-405.
145. Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. *Hepatol Int* 2011;5:654-63.
146. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. *Hepatology* 2011;53:1100-8
147. Ayers CL, Firan M, Pillai V, Lee WM, Karandikar NJ. Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection. *Viral Immunol* 2011;24:119-29
148. Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D; HALT-C Trial Study Group. Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. *Am J Gastroenterol* 2011;106:884-93
149. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. *Gastroenterology* 2011;140:840-9
150. Ajmera V, Xia G, Vaughan G, Forbi J, Ganova-Raeva LM, Khudyakov Y, Opio CK, Taylor R, Restrep R, Munoz S, Fontana RJ, Lee WM and the ALFSG. What factors determine the severity of hepatitis A related acute liver failure? *J Viral Hep* 2011;18:e174-8.

151. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM, Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. *Hepatology* 2011;53:567-76.
152. Stravitz RT, Lefkowitz JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, Manns MP, Norman GL, Lee WM and the ALFSG. Autoimmune acute liver failure: Proposed clinical and histological criteria. *Hepatology* 2011; 53:517-526
153. Dao DY, Balko J, Attar N, Neak E, Yuan HJ, Lee WM, Jain MK. Hepatitis B virus genotype G: Prevalence and impact in HIV/HBV co-infected patients. *J Med Virol* 2011;83:1551-8
154. Taylor RM, Tujios S, Jinjuvadia K, Davern T, Shaikh OS, Han S, Chung RT, Lee WM, Fontana RJ. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. *Dig Dis Sci* 2012;57:777-85
155. Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, Lok ASF, Word RA, Lee WM. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum IgM anti-HBc and HBV DNA levels. *Hepatology* 2012;55:676-684
156. Jain MK, Seremba E, Bhore R, Dao D, Joshi R, Attar N, Yuan HJ, Lee WM. Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. *AIDS Patient Care STDS*. 2012;26:73-80
157. Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: A systematic review. *J Gen Intern Med* 2012;27:861-70.
158. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim A, Lee WM, Sanyal AJ. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. *J Hepatol* 2012;56:129-36.
159. Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM and the ALFSG. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. *Dig Dis Sci* 2012;57:1349-5.
160. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM and the HALT-C Trial Group. Antigen-specific lymphocyte proliferation decreases over time in advanced chronic hepatitis C. *J Viral Hep* 2012;19:404-409.

161. Chung RY, Stravitz RT, Fontana RJ, Schiodt FV, Mehal W, Reddy R, Lee WM. Pathogenesis of Liver Injury in Acute Liver Failure: Meeting Summary. *Gastroenterology* 2012;143:e1-7.
162. Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. *J Med Virol*. 2012; 84: 1913-20.
163. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB; on behalf of the Drug-Induced Liver Injury Network, DILIGEN, EUDRAGENE, the Spanish DILI Registry, and the International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. *Pharmacogenet Genomics* 2012;22:784-795
164. Carpenter TO, Zhang JH, Parra E, Ellis BK, Simpson C, Lee WM, Balko J, Fu L, Wong BY, Cole DE. Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers. *J Bone Miner Res* 2012 28:213-22.
165. Rutherford A, King LY, Hynan LS, Vedvyas C, Lin W, Lee WM, Chung RT; ALF Study Group. Development of an accurate index for predicting outcomes of patients with acute liver failure. *Gastroenterology* 2012;143:1237-43.
166. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA. Failure rates in the hepatocellular carcinoma surveillance process. *Cancer Prev Res*. 2012;5:1124-30.
167. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC; HALT-C Trial Group. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. *J Viral Hepat* 2012;19:404-13.
168. Jain MK, Seremba E, Bhore R, Dao D, Joshi R, Attar N, Yuan HJ, Lee WM. Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. *AIDS Patient Care STDS* 2012;26:73-80.
169. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC and HALT-C Trial. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. *J Viral Hepat* 2012;19:404-13.
170. Lara J, Tavis JE, Donlin MJ, Lee WM, Yuan HJ, Pearlman BL, Vaughan G, Forbi JC, Xia GL, Khudyakov YE. Coordinated evolution among hepatitis C virus genomic

- sites is coupled to host factors and resistance to interferon. *In Silico Biol* 2012;11:213-24.
171. Grant LM, Kleiner DE, Conjeevaram HS, Vuppalanchi R, Lee WM. Clinical and histological features of hepatotoxicity due to temozolomide: a case series. *Dig Dis Sci*, 2013;58:1415-21
172. Chen EY, Baum K, Collins W, Love A, Merz M, Olafsson S, Bjornsson R, Lee WM. Hepatitis E masquerading as drug-induced liver injury. *Hepatology* 2012;56:2420-23.
173. Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. *Clin Gastroenterol Hepatol* 2013;11:1014-20.
174. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? *Am J Gastroenterol* 2013;108:425-32.
175. Chen EY, Lee WM, Hynan LS, Singal AG. A survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors. *J Clin Gastroenterol* 2013;47:800-6
176. Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SC, Greenblatt DJ, Lee WM, and the ALFSG. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042>G (rs 8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A Exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. *J Pharmacol Exp Ther* 2013;345:297-307.
177. Singh S, Hynan LS, Lee WM and the ALFSG. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. *Dig Dis Sci* 2013;58:1397-1402.
178. North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, Quartey NA, Ashitey S, Lee WM, Lisker-Melman M. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. *Gen Hosp Psychiatry* 2013;35:122-8.
179. Lara J, Tavis JE, Donlin MJ, Lee WM, Yuan HJ, Pearlman BL, Vaughan G, Forbi JC, Xia GL, Khudyakov YE. Coordinated evolution among hepatitis C genomic sites is coupled with host factors and resistance to interferon. *In Silico Biol* 2011-12;11:213-24.

180. Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. *Antimicrob Agents Chemother* 2013;57:1115-20.
181. Rangnekar AS, Ellerbe C, Durkalski V, McGuire B, Lee WM, Fontana RJ. Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients. *Liver Transpl* 2013;19:991-1000.
182. Stravitz RT, Sanyal AJ, Reisch J, Bajaj JS, Mirshahi F, Cheng J, Lee WM and the Acute Liver Failure Study Group. Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. *Liver Int* 2013;33:1324-31.
183. Opio CK, Seremba E, Ocamo P, Lalitha R, Kagimu M, Lee WM. Diagnosis of alcohol misuse and alcoholic liver disease among patients in the medical emergency admission service of a large urban hospital in Sub-Saharan Africa; a cross sectional study. *Pan Afr Med J* 2013;15:23-30.
184. Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, Brown RS Jr; the Acute Liver Failure Study Group. Steroid use in acute liver failure. *Hepatology* 2014;59:612-21.
185. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. *Hepatology* 2014;59:661-70.
186. Metushi IG, Sanders C, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-CYP antibodies in patients with isoniazid-induced liver failure. *Hepatology* 2014;59:1084-93.
187. Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N, Fontana RJ, Watkins PB, Lee WM, Reddy KR, Stolz A, Talwalkar J, Davern T, Saha D, Bell LN, Barnhart H, Gu J, Serrano J, Bonkovsky HL. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. *PLoS One* 2013;27;8:e81974.
188. Court MH, Peter I, Hazarika S, Vasiadi M, Greenblatt DJ, Lee WM; Acute Liver Failure Study Group. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. *Drug Metab Dispos* 2014;42:28-32.
189. Karvellas CJ, Cavazos J, Battenhouse H, Durkalski V, Balko J, Sanders C, Lee WM; for the US Acute Liver Failure Study Group. Effects of antimicrobial prophylaxis

and blood stream infections in patients with acute liver failure: A retrospective cohort study. *Clin Gastroenterol Hepatol* 2014;12:1942-9.

190. Metushi IG, Lee WM, Uetrecht J. IgG3 is the dominant subtype of anti-Isoniazid and anti-P450 antibodies in patients with isoniazid-induced liver failure. *Chem Res Toxicol* 2014;27:738-40.
191. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwalkar JA; on behalf of the DILIN network. Idiosyncratic drug induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology* 2014 Mar 26 epub
192. Mellinger JL, Rossaro L, Naugler WE, Nadig SN, Appelman H, Lee WM, Fontana RJ. Epstein-Barr virus (EBV) related acute liver failure: A case series from the US Acute Liver Failure Study Group. *Dig Dis Sci* 2014;59:1630-7.
193. Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS. Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. *Clin Infect Dis* 2014;58:960-9.
194. Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM; U.S. Acute Liver Failure Study Group. Outcomes and complications of intracranial pressure monitoring in acute liver failure: A retrospective cohort study. *Crit Care Med* 2014;42:1157-67.
195. Fontana RJ, Ellerbe C, Durkalski VE, Rangnekar A, Reddy KR, Stravitz T, McGuire B, Davern T, Reuben A, Liou I, Fix O, Ganger DR, Chung RT, Schilsky M, Han S, Hynan LS, Sanders C, Lee WM; The US Acute Liver Failure Study Group. Two-year outcomes in initial survivors with acute liver failure: Results from a prospective, multicenter study. *Liver Int* 2015;35:370-80.
196. Tujios SR, Hynan LS, Vazquez MA, Larson AM, Seremba E, Sanders CM, Lee WM; Acute Liver Failure Study Group. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. *Clin Gastroenterol Hepatol*. 2015;13:352-9.
197. McGill MR, Staggs VS, Sharpe MR, Lee WM, Jaeschke H; Acute Liver Failure Study Group. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. *Hepatology* 2014;60:1336-45.
198. Dubin PH, Yuan HJ, Devine RK, Hynan LS, Jain MK, Lee WM; Acute Liver

- Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. *J Med Virol* 2014;86:1507-14.
199. Long D, Fix OK, Deng X, Seielstad M, Lauring AS; Acute Liver Failure Study Group. Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis A virus infection. *J Med Virol* 2014;86:1661-8.
 200. Karvellas CJ, Stravitz RT, Battenhouse H, Lee WM, Schilsky ML; for the US Acute Liver Failure Study Group. Therapeutic hypothermia in acute liver failure: A multi-center retrospective cohort analysis. *Liver Transpl* 2015;21:4-12.
 201. Rich NE, Sanders C, Hughes RS, Fontana RJ, Stravitz RT, Fix O, Han SH, Naugler WE, Zaman A, Lee WM. Malignant Infiltration of the liver presenting as acute liver failure. *Clin Gastroenterol Hepatol* 2014;13:1025-8.
 202. Woolbright BL, McGill MR, Staggs VS, Winefield RD, Gholami P, Olyae M, Sharpe MR, Curry SC, Lee WM, Jaeschke H, the Acute Liver Failure Study Group. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. *Toxicol Sci* 2014;142:436-44.
 203. Laursen TL, Sandahl TD, Støy S, Schiødt FV, Lee WM, Vilstrup H, Thiel S, Grønbaek H; US Acute Liver Failure Study Group. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. *Liver Int* 2015;35:756-63.
 204. Zacharias T, Wang W, Dao D, Wojciechowski H, Lee WM, Do S, Singal AG. HBV Outreach programs significantly increase knowledge and vaccination rates among Asian Pacific Islanders. *J Community Health* 2015;40:619-24.
 205. Foureau DM, Walling TL, Maddukuri V, Anderson W, Culbreath K, Kleiner DE, Ahrens WA, Jacobs C, Watkins PG, Fontana RJ, Chalasani N, Talwalkar J, Lee WM, Stolz A, Serrano J, Bonkovsky HL. Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. *Clin Exp Immunol* 2014;180:40-51.
 206. Speiser JL, Durkalski VL, Lee WM Random forest classification of etiologies for an orphan disease. *Stat Med* 2014;34:887-99.
 207. Dubin PH, Sclair SN, Rico R, Boehme AK, Chen EY, Martin P, Lee WM. Low SVR rates in clinical practice for treating Genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir. *Dig Dis Sci* 2015;60:272-4.
 208. Woolbright BL, McGill MR, Staggs VS, Winefield RD, Gholami P, Olyae M, Sharpe MR, Curry SC, Lee WM, Jaeschke H; Acute Liver Failure Study Group. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced

acute liver failure patients. *Toxicol Sci* 2014;142:436-44.

209. Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, Shuhart MC, Lau DT, Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SH, Ganova-Raeva LM, Chang KM, Lok AS; Hepatitis B Research Network; Hepatitis B Research Network. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. *Clin Gastroenterol Hepatol* 2015;13:183-92.
210. Zacharias T, Wang W, Dao D, Wojciechowski H, Lee WM, Do S, Singal AG. HBV outreach programs significantly increase knowledge and vaccination rates among Asian Pacific Islanders. *J Community Health* 2015;40:619-24.
211. Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH; US Drug-Induced Liver Injury Network Investigators. Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. *Clin Gastroenterol Hepatol*. 2015;148:1340-52.
212. Speiser JL, Lee WM, Karvellas CJ; US Acute Liver Failure Study Group. Predicting outcome on admission and post-admission for acetaminophen-induced acute liver failure using classification and regression tree models. *PLoS One* 2015; April 17 epub.
213. Basta G, Del Turco S, Navarra T, Lee WM; Acute Liver Failure Study Group. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure. *Liver Transpl* 2015;21:847-54.
214. Srungaram P, Rule JA, Yuan HJ, Reimold A, Dahl B, Sanders C, Lee WM; Acute Liver Failure Study Group. Plasma osteopontin in acute liver failure. *Cytokine* 2015 ;73:270-6.
215. Serper M, Wolf MS, Parikh NA, Tillman H, Lee WM, Ganger DR. Risk factors, clinical presentation, and outcomes in overdose with acetaminophen alone or with combination products: Results from the Acute Liver Failure Study Group. *J Clin Gastroenterol* 2016;50:85-91.
216. Apica BS, Seremba E, Rule J, Yuan H-J, Lee WM. High prevalence of occult hepatitis B infection in an African urban population. *J Med Virol* 2016;88:674-80.
217. Kaur G, Leslie EM, Tillman H, Lee WM, Swanlund DP, Karvellas CJ; US Acute Liver Failure Study Group. Detection of ophthalmic acid in serum from acetaminophen-induced acute liver failure patients is more frequent in non-survivors. *PLoS One*. 2015;10:e0139299.

218. Rule JA, Hynan LS, Attar N, Sanders C, Korzun WJ, Lee WM; Acute Liver Failure Study Group. Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure. *PLoS One*. 2015;10:e0138566.
219. Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. *Am J Gastroenterol*. 2015;110:1450-9.
220. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. *Gastroenterology*. 2016;150:684-695.
221. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. *Gastroenterology* 2015;148:1340-52.
222. Rosen HR, Biggins SW, Niki T, Gralla J, Hillman H, Hirashima M, Schilsky M, Lee WM; Acute Liver Failure Study Group (ALFSG). Association between plasma level of Galectin-9 and survival of patients with drug-induced acute liver failure. *Clin Gastroenterol Hepatol*. 2016;14:606-612.
223. Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lisman T, Lee WM; Acute Liver Failure Study Group. Thrombocytopenia is associated with multi-organ system failure in patients with acute liver failure. *Clin Gastroenterol Hepatol*. 2016;14:613-620.
224. Reddy KR, Ellerbe C, Schilsky M, Stravitz RT, Fontana RJ, Durkalski V, Lee WM; Acute Liver Failure Study Group. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the US. *Liver Transpl*. 2015;22:505-515.
225. Reuben A, Fontana RJ, Davern T, McGuire B, Stravitz R, Lee WM. Outcomes in adults with acute liver failure (ALF) from 1998-2013: An observational cohort study. *Ann Intern Med* 2016;164:724-32.
226. Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. *Clin Gastroenterol Hepatol* 2016;14:1199-1206.
227. Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee WM, Ganger D. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. *Am J Gastroenterol* 2016;111:958-65.
228. Karvellas CJ, Tillman H, Leung AA, Lee WM, Schilsky ML, Hameed B, Todd Stravitz R, McGuire BM, Fix OK; United States Acute Liver Failure Study

Group. Acute liver injury and acute liver failure from mushroom poisoning in North America. *Liver Int* 2016;36:1043-50.

229. Maina I, Rule JA, Wians Jr, FH, Poirier M, Grant L, Lee WM, for the Acute Liver Failure Study Group. α -Glutathione S-Transferase: A new biomarker for liver injury? *J Appl Lab Med* 2016;1:119-122.
230. Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana RJ, et al. Drug-Induced Liver Injury Network (DILIN). Liver injury from non-steroidal anti-inflammatory drugs in the United States. *Liver Int* 2016;36:603-9.
231. Karvellas CJ, Cardoso FS, Gottfried M, Reddy KR, Hanje AJ, Ganger D, Lee WM; US Acute Liver Failure Study Group. HBV-associated acute liver failure after immunosuppression and risk of death. *Clin Gastroenterol Hepatol* 2017;15:113-22.
232. Fontana RJ, Engle RE, Scaglione S, Araya V, Shaikh O, Tillman H, Attar N, Purcell RH, Lee WM; US Acute Liver Failure Study Group. The role of hepatitis E virus infection in adult Americans with acute liver failure. *Hepatology* 2016;64:1870-80.
233. Fix OK, Liou I, Karvellas CJ, Ganger DR, Forde KA, Subramanian RM, Boylan A, Hanje J, Stravitz RT, Lee WM; Acute Liver Failure Study Group. Development and pilot of a checklist for management of acute liver failure in the Intensive Care Unit. *PLoS One* 2016 May 13.
234. Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF; US Acute Liver Failure Study Group. Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. *Hepatology* 2017; 65:938-49.
235. Parekh J, Matei VM, Canas-Coto A, Friedman D, Lee WM; and the Acute Liver Failure Study Group. Budd-Chiari syndrome causing acute liver failure: A multicenter case series. *Liver Transpl* 2017;23:135-42.
236. Roberts DW, Lee WM, Hinson JA, Bai S, Swearingen CJ, Stravitz RT, Reuben A, Letzig L, Simpson PM, Rule J, Fontana RJ, Ganger D, Reddy KR, Liou I, Fix O, James LP. An immunoassay to rapidly measure acetaminophen protein adducts accurately identifies patients with acute liver injury or failure. *Clin Gastroenterol Hepatol* 2017;15:555-62.
237. Davis BC, Tillman H, Chung RT, Stravitz RT, Reddy KR, Fontana RJ, McGuire B, Davern T, Lee WM. Heat stroke leading to acute liver injury and failure: A case series from the Acute Liver Failure Study Group. *Liver Int* 2017;37:509-13.

238. Randesi M, Levran O, Correa da Rosa J, Hankins J, Rule J, Kreek MJ, Lee WM. Association of variants of arginine vasopressin and arginine vasopressin receptor 1A, with severe acetaminophen liver injury. *Cell Molec Gastroenterol Hepatol* 2017;3:500-05.
239. Koch DG, Speiser JL, Durkalski V, Fontana RJ, Davern T, McGuire B, et al. The natural history of acute liver injury. *Am J Gastroenterol* 2017;112:1389-96.
240. Chowdhary V, Teng KY, Thakral S, Zhang B, Lin CH, Wani N, Bruschiweiler-Li L, Zhang X, James L, Yang D, Junge N, Brüschiweiler R, Lee WM, Ghoshal K. miRNA-122 protects mice and human hepatocytes from acetaminophen toxicity by regulating cytochrome P450 family 2 subfamily A member 2 and E member 1 expression. *Am J Pathol* 2017;187:2758-2777.
241. Hezode C, Colombo M, Bourliere M, Spengler U, Ben-Ari Z, Strasser S, Lee WM et al. Elbasvir/Grazoprevir for patients with Hepatitis C virus infection and inherited blood disorders: A Phase III Study. *Hepatology* 2017;66:736-45.
242. Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF; US Acute Liver Failure Study Group. The association between FABP7 serum levels with survival and neurological complications in acetaminophen-induced acute liver failure: a nested case-control study. *Ann Intensive Care* 2017;7:99-103.
243. Somasekar S, Lee D, Rule J, Naccache SN, Stone M, Busch MP, Sanders C, Lee WM, Chiu CY. Viral surveillance in serum samples from patients with acute liver failure by metagenomic next-generation sequencing. *Clin Infect Dis* 2017;65:1477-85.
244. Stravitz RT, Gottfried M, Durkalski V, Fontana RJ, Hanje AJ, Koch D, Hameed B, Ganger D, Subramanian RM, Bukofzer S, Ravis WR, Clasen K, Sherker A, Little L, Lee WM; Acute Liver Failure Study Group. Safety, tolerability and pharmacokinetics of L-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. *Hepatology* 2018;67:1003-13.
245. Pezzia C, Sanders C, Welch S, Bowling A, Lee WM; Acute Liver Failure Study Group. Psychosocial and behavioral factors in acetaminophen-related acute liver failure and liver injury. *J Psychosom Res* 2017;101:51-57.
246. Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ, for the US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. *Hepatology* 2017;112:1389-96.
247. Rubin JB, Hameed B, Gottfried M, Lee WM, Sarkar M. Acetaminophen induced liver disease is more common and more severe in women. *Clin Gastroenterol Hepatol* 2018;16:936-46.

248. Stravitz RT, Ellerbe C, Durkalski V, Schilsky M, Fontana RJ, Peterseim C, Lee WM. Bleeding complications of acute liver failure. *Hepatology* 2018; 67:1931-42.
249. Kok B, Lester ELW, Lee WM, Hanje AJ, Stravitz RT, Girgis S, et al; United States Acute Liver Failure Study Group. Acute liver failure from tumor necrosis factor- α antagonists: Report of four cases and literature review. *Dig Dis Sci* 2018;63:1654-66.
250. Yang E, Peng L, Lee WM. Multiple admissions for acetaminophen over-dose; Acetaminophen frequent fliers, a new entity? *Hepatology* 2018;68:1197-99.
251. Ganger DR, Rule J, Rakela J, Bass N, Reuben A, Stravitz RT, Sussman N, Larson AM, James L, Chiu C, Lee WM; Acute Liver Failure Study Group. Acute liver failure of indeterminate etiology: A comprehensive systematic approach by an expert committee to establish causality. *Am J Gastroenterol* 2018;113:1319-28.
252. Little L, Rule J, Peng L, Gottfried M, Lee WM for the Acute Liver Failure Study Group. Herpes simplex virus-associated acute liver failure often goes unrecognized. *Hepatology* 2019;69:917-919.
253. Ajmera V, Huang H, Dao D, Feld JJ, Lau DT, Patel K, Rule JA, Daly M, Lee WM, Chung RT. Host genetic variant in CXCL16 may be associated with hepatitis B virus-related acute liver failure. *Research Letter. Cell Molec Gastroenterol Hepatol* 2019;7:477-479.
254. Bonkovsky HL, Barnhart HX, Foureau DM, Steuerwald N, Lee WM, Gu J et al. Cytokine profiles in acute liver injury—Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group. *PLoS 1*; on line 10/25/2018.
255. Spivak I, Arora J, Meinzer C, Durkalski-Mauldin V, Lee WM, Trautwein C, Fontana RJ, Strnad P. Low serum hepcidin is associated with reduced shorter survival in adults with acute liver failure. *Hepatology* 2019;69:2136-2149.
256. Leventhal TM, Gottfried M, Olson JC, Subramanian RM, Hameed B, Lee WM; Acute Liver Failure Study Group. Acetaminophen is undetectable in plasma form more than half of patients believed to have acute liver failure due to overdose. *Clin Gastro Hepatol* 2019;17:2110–2116.
257. Brahmania M, Lombardero M, Hansen BE, Terrault NA, Lok AS, Perrillo RP, Belle SH, Di Bisceglie AM, Feld JJ, Lee WM, Fried MW, Janssen HLA; Hepatitis B Research Network. Association between severe serum alanine aminotransferase

flares and hepatitis B e antigen seroconversion and HBV DNA decrease in untreated patients with chronic HBV infection. *Clin Gastroenterol Hepatol* 2019;17:2541-

258. Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, Terrault N and HBRN. Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. *J Viral Hepat* 2019;26:856-865.
259. Slowik V, Borude P, Jaeschke H, Woolbright BL, Lee WM, Apte U and ALFSG. Leukocyte cell derived chemotaxin-2 (Lect2) as a predictor of survival in adult acute liver failure. *Transl Gastroenterol Hepatol* 2019;20:17
260. Chang KM, Traum D, Park JJ...Betts MR, Lee WM, Lok ASF and HBRN. Distinct phenotype and function of circulating V δ 1+ and V δ 2+ gamma δ T-cells in acute and chronic hepatitis B. *PLoS Pathog* 2019;15:e1007715
261. Singh S, Hynan LS, Rule JA, Lee WM. Changes in alpha-fetoprotein and Gc-globulin in relation to outcomes in non-acetaminophen acute liver failure. *Liver Int* 2019;39:2368-73.
262. Bajaj JS, Bloom PP, Chung RT, Hassanein TI...Lee WM,... Puurunen MK, Lawitz E. Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: Implications for trial design and clinical practice. *Am J Gastroenterol* 2020; 115:783-785.
263. Stravitz RT, Lee WM. Seminar: Acute Liver Failure. *Lancet* 2019;394:869-881.
264. Dong V, Sun K, Gottfried M, Cardoso FS, McPhail MJ, Stravitz RT, Lee WM, Karvellas CJ. Significant lung injury and its prognostic significance in acute liver failure: A cohort analysis. *Liver Int* 2020;40:654-663.
265. Rakela J, Rule J, Ganger D, Lau J, Cunningham J, Dehankar M, Baheti S, Lee WM. Whole exome sequencing among 36 patients with indeterminate acute liver failure: A pilot study. *Clin Transl Gastroenterol* 2019: Oct 10, epub ahead of print.
266. Zhou K, Wahed AS, Cooper S, Di Bisceglie AM, ...Lee WM, ...Terrault N. Phase transition is infrequent among North American adults with e-antigen negative chronic hepatitis B and low level viremia. *Am J Gastroenterol* 2019;114:1753-63.
267. Simmons OK, Meinzer C, Rule J, Lee WM and ALFSG. Liver transplantation for acetaminophen-induced acute liver failure: role of psychiatric comorbidity in listing decisions and outcomes. *Dig Dis Sci* 2020;65:1861-1868.
268. Oaks Z, Jimah J, Grossman CC, Beckfor M, Kelly R, Banerjee S, Nilandn B, Miklossy G, Kuloglu Z, Kansu A, Lee W, Szonyi L, Bankk K, Perl A. Transaldolase

- haploinsufficiency in subjects with acetaminophen-induced liver failure. *J Inherit Metab Dis* 2020;43:496-506.
269. Casey LC, Fontana RJ, Aday A, Nelson SB, Rule JA, Gottfried M, Tran M, Lee WM. Acute liver failure (ALF) in pregnancy: How much is pregnancy-related? *Hepatology* 2020;72:1366-1377.
270. Puri P, Lee WM, Fontana RJ, Kim NK, Durkalski V, McGuire BM, Liou I, Pezzia C, Stravitz RT and ALFSG. Alcohol consumption is associated with the severity and outcome of acute liver injury/failure. *Liver Int* 2020;40:360-367.
271. Camarata M, Gottfried M, Rule JA, Ala A, Lee WM, Stravitz RT, Schilsky ML. Outcomes of acute liver injury (ALI) in adults due to Wilson Disease: Is survival without transplant possible? *Liver Transpl* 2020;26:330-336.
272. Ren Y, Xu Y, Lee WM, Di Bisceglie AM, Fan X. In-depth serum virome analysis in patients with acute liver failure of indeterminate etiology. *Arch Virol* 2020;165:127-135.
273. Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF. Elevated serum liver-type fatty acid binding protein levels in non-acetaminophen acute liver failure patients with organ dysfunction. *Dig Dis Sci* 2020, online ahead of print.
274. Patidar K, Davis BC, Slaven JE, Ghabril MW, Chandrashekar AK, Lee WM, Stravitz RT. Admission Factor V predicts transplant-free survival in acute liver failure. *Dig Dis Sci* 2020; online ahead of print.
275. Glavind E, Gotthardt DN, ...Lee WM, Gronbaek H. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in Wilson disease. *Orphanet J Rare Dis* 2020;15:173.
276. Anugwom CM, Parekh JR, Hwang C, MacConmara M, Lee WM, Leventhal TM. Comparison of clinical outcomes of induction regimens in patients undergoing liver transplantation for acute liver failure. *Liver Transpl* 2021;27:27-33.
277. Lee WM, King WC, Schwarz KB, Rule J, Lok ASF. Prevalence and clinical features of patients with concurrent HBsAg and anti-HBs: Evaluation of the Hepatitis B Network Cohort. *J Viral Hepat* 2020;27:922-931.
278. Driever EG, Stravitz RT, Zhang J, Adelmeijer J, Durkalski V, Lee WM, Lisman T. VWF/ADAMTS13 imbalance, but not global coagulation or fibrinolysis, is associated with outcome and bleeding in acute liver failure. *Hepatology* 2020; epub ahead of print.

279. MacDonald AJ, Speiser JL, Ganger DR, Nilles KM, Orandi BJ, Larson AM, Lee WM, Karvellas CJ for the US ALFSG. Clin Gastroenterol Hepatol 2020; epub ahead of print.
280. Lee WM. Acetaminophen toxicity: A history of serendipity and unintended consequences. Clin Liver Dis;16:NO S1, October 2020.
281. James LP, McGill MR, Roberts DW, Hinson JA, Lee WM. Advances in biomarker development in acetaminophen toxicity. Adv Clin Chem 2020;98:35-50.
282. Montague SJ, Hicks SM, Lee CS, Coupland LA, Parish CR, Lee WM, Andrews RK, Gardiner EE. Fibrin exposure triggers α IIb β 3-independent platelet aggregate formation, ADAM10 activity and glycoprotein VI shedding in a charge- dependent manner. J Thromb Haemost. 2020;18:1447-1458.
283. Patidar KR, Davis BC, Slaven JE, Ghabril MS, Kubal CA, Lee WM, Stravitz RT. Admission factor V predicts transplant-free survival in acute liver failure. Dig Dis Sci 2021;66:619-627.
284. Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF; US Acute Liver Failure Study Group. Elevated serum liver-type fatty acid binding protein levels in non-acetaminophen acute liver failure patients with organ dysfunction. Dig Dis Sci 2021;66:273-283.
285. Shan Z, Li L, Atkins CL, Wang M, Wen Y, Jeong J, Moreno NF, Feng D, Gui X, Zhang N, Lee CG, Elias JA, Lee WM, Gao B, Lam FW, An Z, Ju C. Chitinase 3-like-1 contributes to acetaminophen-induced liver injury by promoting hepatic platelet recruitment. Elife 2021;10:e68571.
286. Tavabie OD, Karvellas CJ, Salehi S, Speiser JL, Rose CF, Menon K, Prachalias A, Heneghan MA, Agarwal K, Lee WM, McPhail MJW, Aluvihare VR; United States Acute Liver Failure Study Group. A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen- induced acute liver failure. J Hepatol 2021;75:424-434.
287. Fontana RJ, Engle RE, Gottfried M, Hammed B, Hanje J, Durkalski V, Kleiner DE, Nguyen H, Nishimura N, Lee WM, Farci P; Acute Liver Failure Study Group. Role of hepatitis E virus infection in North American patients with severe acute liver injury. Clin Transl Gastroenterol 2020;11:e00273.
288. Lee WM. Acetaminophen toxicity: A history of serendipity and unintended consequences. Clin Liver Dis 2020;16(Suppl 1):34-44.
289. MacDonald AJ, Speiser JL, Ganger DR, Nilles KM, Orandi BJ, Larson AM, Lee WM, Karvellas CJ; US Acute Liver Failure Study Group. Clinical and neurologic outcomes in acetaminophen-induced acute liver failure: A 21-Year multicenter cohort study. Clin Gastroenterol Hepatol 2020;:S1542-3565.

290. Driever EG, Stravitz RT, Zhang J, Adelmeijer J, Durkalski V, Lee WM, Lisman T. VWF/ADAMTS13 imbalance, but not global coagulation or fibrinolysis, is associated with outcome and bleeding in acute liver failure. *Hepatology* 2021;73:1882-1891.
291. Glavind E, Gotthardt DN, Pfeiffenberger J, Sandahl TD, Bashlekov T, Willemoe GL, Hasselby JP, Weiss KH, Møller HJ, Vilstrup H, Lee WM, Schilsky ML, Ott P, Grønbaek H. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. *Orphanet J Rare Dis* 2020;15:173.
292. Anugwom CM, Parekh JR, Hwang C, MacConmara M, Lee WM, Leventhal TM. Comparison of clinical outcomes of induction regimens in patients undergoing liver transplantation for acute liver failure. *Liver Transpl* 2021;27:27-33.

BOOK CHAPTERS, CASE REPORTS, EDITORIALS AND REVIEWS

293. Lee WM. Cellular and humoral immunity in viral hepatitis. *Amer J Clin Path* 1976;65:866-9
294. Lee WM, Lebwohl O, Chien S. Hyperviscosity syndrome due to hyperglobulinemia in chronic active hepatitis. *Gastroenterology* 1978;74:918-921.
295. Brasitus TA, Gold RP, Kay RH, Magun AM, Lee WM. Intestinal strongyloidiasis: A case report and review of the literature. *Amer J Gastro* 1980;73:65-69.
296. Lee WM. Management of massive ascites utilizing ascites reinfusion. *J Clin Gastroenterol* 1982;4:87-92.
297. Lee WM. Treating bleeding esophageal varices: Less is more. (Editorial) *J Clin Gastroenterol* 1982;4:181-2.
298. Lee WM, Silva F, Price JB. Gastrin secreting tumor of the duodenum (G-cell apudoma) associated with secondary biliary cirrhosis. *Cancer* 1982;49:2596-2601.
299. Marsh WH, Cunningham JT, Lee WM. Hepatomegaly and ascites in an elderly woman with polycythemia vera. *J Clin Gastroenterol* 1983;5:367-75.
300. Lee WM. Right upper quadrant pain and hepatomegaly in a 28 year old woman. *J Clin Gastroenterol* 1984;6:261-6.
301. Loevinger EH, Vujic I, Lee WM, Anderson MC. Hepatic rupture associated with pregnancy: Diagnosis by CT and angiography with transcatheter embolotherapy. *Obstet Gynecol* 1985;65:281-4.

302. Lee WM. Pregnancy and Chronic Liver Disease in Gleicher N, ed. *Principles of Medical Therapy in Pregnancy*. Plenum Publishing Corp., New York. p. 848-852, 1985
303. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Lee WM. Evidence of circulating Gc:G-actin complexes in health and disease. *Vitamin D; Chemical, biochemical and clinical update* (Norman AW, Schaefer K, Grigoleit H-G, and Herraton DV, eds) Walter De Gruyter & Co., Berlin, 1103-1104, 1985
304. Lee WM. The antigens and antibodies of hepatitis B: A Review. *J SC Med Assoc* 1986;82:613-619.
305. Lee WM. A hepatologist looks at the irritable bowel syndrome. (Editorial) *J Clin Gastroenterol* 1986;8:609-610.
306. Lee WM. Acute and Chronic Viral Hepatitis (chapter) in *Conn's Current Therapy 1988*, Robert E. Bakel, ed., W.B. Saunders and Co., Philadelphia, pp. 426-431.
307. Lee WM, Denton WT. Chronic active hepatitis and cirrhosis due to methyldopa. *J SC Med Assoc* 1989;85:75-79.
308. Lee WM. Gastroenterology (chapter, p. 165-190) in *Critical Care Pearls* 1989, S Sahn, J Heffner, eds. Hanley and Belfus Inc. Philadelphia.
309. Wootton FT, Rhodes DF, Lee WM, Fitts CT. Colonic necrosis with Kayexelate/sorbitol enemas after renal transplantation. *Ann Intern Med* 1989;111: 947-49.
310. Lee WM. Metabolic liver diseases. *Trans Assn LIMDA*. 72: 105-110, 1989
311. Lee WM. Viral Hepatitis (Review of world literature for 1989) *Curr Opin Inf Dis* 1990;3:237-245.
312. Krueger K, Hoffman BJ, Lee WM. Hepatic infarction associated with eclampsia. *Am J Gastro* 1990;85:588-592.
313. Hoffman BJ, Pate MB, Marsh WH, Lee WM. Cardiomyopathy unrecognized as a cause of hepatic failure. *J Clin Gastroenterol* 1990;12:306-309.
314. Lee WM. Hepatitis C (review of the world's literature for 1989-90) *Curr Opin Inf Dis* 1990;3:789-795.
315. Lee WM. Hepatitis update: diagnosis, treatment and prevention. *Modern Medicine* 1990;58:46-65.

316. Rhodes DF, Lee WM, Wingard JR, Santos GW, Pavy MD, Shaw BW, Wood RP, Sorrell MF, Markin RS. Orthotopic liver transplantation for graft-versus-host disease following bone marrow transplantation. *Gastroenterology* 1990;99:537-40.
317. Lee WM. Interferon as treatment for viral hepatitis: a progress report. *J SC Med Assoc* 1990;86:440-444.
318. Arterburn JA, Lee WM, Wood RP, Shaw BW, Markin RS. Orthotopic liver transplantation for cholesteryl ester storage disease. *J Clin Gastroenterol* 1991;13:482-6.
319. Lee WM. Pregnancy and Chronic Liver Disease in Gleicher N, ed. *Principles and Practice of Medical Therapy in Pregnancy*. p. 976-981, Appleton and Lange Co. East Norwalk. Second Edition, 1992.
320. Lee WM. Pregnancy in patients with chronic liver disease. In Riely CA, Abell TL, eds. *Gastrointestinal and Liver Problems in Pregnancy, Gastro Clin North America*, p.889-903, WB Saunders Co. Philadelphia Pa, 1992.
321. Lee WM. Where is the dividing line between autoimmune hepatitis and hepatitis C? *Gastroenterology* 1992;102:1814-1815.
322. Foust R, Lee WM. Gastrointestinal vasculitis. In EC LeRoy, Ed. *Systemic Vasculitis*, 1992.
323. Lee WM. Intrahepatic shunts: a new era? *Gastroenterology* 1992;103: 1357-1358.
324. Lee WM. The silent epidemic of hepatitis C. *Gastroenterology* 1993;104: 661-663.
325. Lee WM. Should we transplant hepatitis C positive organs? *Gastroenterology* 1993;105:300-302.
326. Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA. Mooren's corneal ulcers and hepatitis C virus infection (letter). *N Engl J Med* 1993;329:62,
327. Lee WM. Review article. Drug-induced hepatotoxicity. *Aliment Pharm Therapeut* 1993;7:477-485,.
328. Lee WM. Acute liver failure: Is anything really effective short of transplantation? In *Difficult Decisions in Gastroenterology*, Barkin JS and Rodgers AI. editors, p. 141-146, 1994

329. Lee WM. Gastroenterologists: Get to know gelsolin! *Gastroenterology* 1994;106:813-814,.
330. Lee WM. Acute liver failure. in *Advances in the management of hepatic disease: clarifying the issues*. *Am J Med* 1994;96:3S-9S,.
331. Lee WM. Total hepatectomy for acute liver failure: don't take out my liver! *Gastroenterology* 1994;107: 894-897.
332. Murakami C, Bodenheimer H, Lee WM. Autoimmune thrombocytopenic purpura during interferon alfa-2b treatment for chronic hepatitis C. *Am J Gastroenterol* 1994;89:2244-2245.
333. Lee WM. Mapping a strategy for curing hepatitis C. *Gastroenterology* 1995;108:945-946.
334. Lahoti S, Lee WM. Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents. *Gastroenterol Clin North Am* 1995;24:907-22.
335. Lee WM. Acute liver failure in *Gastroenterology and Hepatology: The Comprehensive Visual Reference*. Vol 1. The Liver eds. Feldman M, Maddrey WC. Current Medicine, Philadelphia, 1996, p. 7.1-7.16.
336. Lee WM and Maddrey WC. Acute liver failure and transplantation: a symposium, in *Liver Transplant Surg* 1995;1:176-206.
337. Lee WM. The selling of acetaminophen. *Gastroenterology* 1995;109:2043-2046.
338. Lee WM. Acute Liver Failure in *Current Practice of Medicine, Gastroenterology/Hepatology* volume, Willis C. Maddrey, editor, Current Medicine, Philadelphia, 1996, pp. 5.1-5.7.
339. Lee WM. Medical management of acute liver failure. In Lee WM and Williams R, Eds. *Acute Liver Failure*. Cambridge University Press, Cambridge UK, 1997, pp. 115-131.
340. Lee WM and Williams R, Eds. *Acute Liver Failure*. Cambridge University Press, Cambridge UK, 1997. 300 page text.
341. Lee WM. Editorial: Prostaglandins for clinical use: Are we there yet? *Liver Transplant Surg* 1996;2:240-241.

342. Lee WM, Sorrell MF. Editorial. Developing a world view toward acute liver failure. *Hepatology* 1996;24:270-71.
343. Lee WM. Specific hepatitis C virus NS5A sequences determine the outcome of interferon treatment. *Gastroenterology* 111:1152-1154,1996.
344. Lee WM. Management of acute liver failure. *Semin Liver Dis* 1996;16:369-78.
345. Schiødt FV, Jain R, Lee WM. Gastroenterology chapter in *Critical Care Pearls* 1997, 2nd edition, S Sahn, J Heffner, eds. Hanley and Belfus Inc. Philadelphia.
346. Lee WM. Drug-induced liver injury. *IM-Internal Medicine* July 1997, pp. 19-32.
347. Peterson WL, Lee WM. Contempo: Gastroenterology and Hepatology (Review of year's literature) *JAMA* 277:1858-60, 1997.
348. Lee WM. Therapy of chronic hepatitis C: Interferon alpha 2a trials. NIH Consensus Development Conference Proceedings. *Hepatology* 26;89S-95S, 1997.
349. Hamid SV, Lee WM. Pregnancy and Chronic Liver Disease in Gleicher N, ed. *Principles and Practice of Medical Therapy in Pregnancy*. p., Appleton and Lange Co. East Norwalk. Third Edition, 1998.
350. Lee WM. Acute Liver Failure in *Current Practice of Medicine*, Gastroenterology/Hepatology volume, Willis C. Maddrey, editor, Current Medicine, Philadelphia, 2nd edition, 1998.
351. Mabee CL, Crippin JS, Lee WM. Review article: interferon and hepatitis C: factors predicting therapeutic outcome. *Aliment Pharm Therapeut* 1998; 12: 509-518.
352. Lee WM, Schiødt FV. Fulminant Hepatic Failure in Schiff's *Diseases of the Liver*, Eighth edition. Schiff ER, Sorrell, MF, Maddrey WC, editors, Lippincott-Raven Publishers, Philadelphia, 1998.
353. Hamid S. Cruz PD Jr. Lee WM. Urticarial vasculitis caused by hepatitis C virus infection: response to interferon alfa therapy *J Am Acad Dermatol* 1998;39:278-80.
354. Lee WM. The case for case reports: Editorial. *Ital J Gastroenterol* 30:318-19, 1998.
355. FV Schiødt, Lee WM. Management of acetaminophen toxicity in *Medical Management of Liver Disease*, Edward L. Krawitt, Editor, Marcel Dekker, New York, 1999.

356. Lee WM, Ed. Hepatitis B, volume 3, no. 2 in series, Clinics in Liver Disease, Philadelphia, WB Saunders and Co., 432 pp., 1999.
357. Malik AH, Lee WM. Hepatitis B therapy: the plot thickens. Editorial. *Hepatology* 1999;30: 579-581.
358. Morales CP, Saboorian MH, Miller GL, Lee WM. Adrenal gland sampling during transjugular liver biopsy leads to misdiagnosis of hepatocellular carcinoma. *Amer J Gastroenterol* 1999;94:3071-2.
359. Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL, Rabkin JM, Lee WM, the Acute Liver Failure Study Group. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. *Liver Transplant Surg* 1999;5:480-484.
360. Malik AH, Lee WM. Review article: Chronic hepatitis B virus infection: Treatment strategies for the next millennium. *Ann Intern Med* 2000;132:723-731.
361. Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, Freise C, Lee WM, Bass NM, the Acute Liver Failure Study Group. Troglitazone induced fulminant hepatic failure: a report of three cases. *Dig Dis Sci* 2000;45:549-553.
362. Ostapowicz G, Lee WM. Acute Liver Failure: the Western experience. *J Gastroenterol Hepatol* 2000;15:480-88.
363. Ostapowicz G, Lee WM. Acute liver failure in *Gastroenterology and Hepatology: The Comprehensive Visual Reference*. Vol 1. The Liver eds. Feldman M, Maddrey WC. Current Medicine, Philadelphia, 2000, pp. 7.1-7.16..
364. Lee WM. Assessing causality in drug-induced liver injury: Editorial. *J Hepatol* 2000;33:338-40.
365. Kumar KS, Lee WM. Chylous ascites with marked elevation of CA-125 in cirrhosis. *Am J Gastroenterol* 2000;95;3313-4.
366. Lee WM. Acute Liver Failure in *Clinical Perspectives in Gastroenterology, AGA*, March-April, 2001,101-110.
367. Malik AH, Collins Jr RH, Saboorian MH, Lee WM. Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis. *Am J Gastroenterol* 2001;96:588-590.

368. Kumar KS, Saboorian MH, Lee WM. Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature. *Dig Dis Sci* 2001;46:2066-73.
369. Schiødt FV, Lee WM. Liver transplantation for acute liver failure: better safe than sorry. *Liver Transplant* 2002;8:1063-4.
370. Ostapowicz GA, Lee WM. Management of acetaminophen toxicity. In *Drug-Induced Liver Disease*, Eds. Deleve L, Kaplowitz N, 2002; pp.327-44.
371. Ocamo P, Lee WM. Don't Forget This Infectious Killer. *The New York Times*, March 1, 2003. Op Ed page article.
372. Schiødt FV, Lee WM. Fulminant liver disease. *Clin Liv Dis* 2003;7:331-49.
373. Schiødt FV and Lee WM. Drug-induced liver injury. In *Yamada Atlas of Gastroenterology and Hepatology*, Philadelphia, PA; Third Edition, pp. 637-40, 2003.
374. Schiødt FV and Lee WM. Drug-induced liver disease. In *Yamada Textbook of Gastroenterology and Hepatology*, Fourth Edition, Philadelphia, PA; pp. 2352-66, 2003.
375. Vaquero J, Jordano Q, Lee WM, Blei AT and the Acute Liver Failure Study Group. Serum S-100b in acute liver failure. Results of the US Acute Liver Failure Study Group. *Liver Transplant* 2003;9:887-8.
376. Lee WM. Acute liver failure in the United States. *Semin Liv Dis* 2003, 23:217-26.
377. Polson J, Lee WM. Acute liver failure in *Gastroenterology and Hepatology: The Comprehensive Visual Reference*. Vol 1. The Liver eds. Feldman M, Maddrey WC. Current Medicine, Philadelphia, 2003, p. 7.1-7.16.
378. Polson J, Lee WM. Acute liver failure in *Atlas of the Liver*. Third edition, Maddrey WC, Feldman M. Current Medicine, Philadelphia, 2003, p. 173-185.
379. Lee WM, and Schiødt FV. Toxic and drug-induced liver disease. Chapter in *Cecil's Textbook of Medicine*, Goldman L, Ausiello D, Eds. Saunders, Philadelphia, PA, 2004: pp. 906-11.
380. Ocamo P and Lee WM. Cirrhosis in *Conn's Current Therapy*, 2004 Edition. Rakei RE, Bope ET, Eds. Saunders, Philadelphia, PA, pp. 513-20.
381. Lee WM. Aches, pains and warning labels. Op Ed piece in *The New York Times*, March 17, 2004.

382. Lee WM. Sounding Board: Acetaminophen Hepatotoxicity and the U.S. Acute Liver Failure Study: Lowering the Risks of Hepatic Failure. *Hepatology*, 2004;40:6-9.
383. Polson J, Lee WM. Analyzing liver transplantation for fulminant hepatic failure at UCLA. Commentary in *Liver Transplantation Worldwide*. *Liver Transplantation* 2004;10:953-4.
384. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. *Toxicol Pathol* 2005;33:155-64.
385. Lee WM. Current view of drug hepatotoxicity from across the pond. *Eur J Hosp Pharm* 2005;11:61-62.
386. Yuan H-J, Lee WM. Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B. *Molecular Medicine* 2007;7:185-197.
387. Ostapowicz GA, Lee WM. Acetaminophen: Pathology and clinical presentation of hepatotoxicity. In *Drug-Induced Liver Disease*, Eds. Deleve L, Kaplowitz N, 2007; pp.389-406.
388. Lee WM. Acetaminophen hepatotoxicity: Changing perceptions of a social/medical issue. *Hepatology*, 2007, 46:966-70.
389. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy I: Hepatocellular injury, in *Drug-Induced Liver Disease*, September 2007 issue of *Clinics in Liver Disease*, WM Lee, Guest Editor, Philadelphia PA.
390. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy II: Atypical hepatic injuries, in *Drug-Induced Liver Disease*, September 2007 issue of *Clinics in Liver Disease*, WM Lee, Guest Editor, Philadelphia PA.
391. Polson J, Lee WM. Editorial: Etiologies of acute liver failure: location, location, location! *Liver Transplant* 2007;13:1364-5.
392. Lee WM. Management of drug-induced acute liver failure. Chapter in *Hepatotoxicity*. 2007, *International Hepatology Updates*, Permanyer Publications, Barcelona, pp. 137-146.
393. Yuan H-J, Lee WM. Non-response to treatment for hepatitis C: Current Management Strategies. *Drugs*, 2008;68:27-42.
394. Seremba E and Lee WM. Drug-induced liver disease. In *Yamada Textbook of Gastroenterology and Hepatology*, Fifth Edition, Philadelphia, PA, 2008.

395. Schiødt FV and Lee WM. Drug-induced liver injury. In Yamada Atlas of Gastroenterology and Hepatology, Philadelphia, PA; Fourth Edition, pp. 637-40, 2008.
396. Lee WM. Acetaminophen-related acute liver failure in the United States. *Hepatology Res* 2008, 38 (Suppl. 1): S3–S8
397. Naderi ASA, Farsian NF, Lee WM. Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis. *Eur J Gastroenterol Hepatol* 2008;20:1115-1117.
398. Lee WM, Seremba E. Etiologies of acute liver failure. *Curr Opin Crit Care* 2008;14:198-201.
399. Lee WM. Liver failure and liver support. *Semin Liver Dis* 2008;28:135-6.
400. Lee WM, Wijdicks E. Acute liver failure and cerebral edema: When the hepatologist meets the neurointensivist. *Neuro Crit Care* 2008;9:1-2.
401. Stravitz RT, Lee WM, Kramer AH, Kramer DJ, Hynan L, Blei AT. Therapeutic hypothermia for acute liver failure: Toward a randomized, controlled trial in patients with advanced hepatic encephalopathy. *Neurocrit Care* 2008;9:90-96.
402. Munoz SJ, Reddy KR, Lee WM and the Acute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. *Neurocrit Care* 2008;9:103-107.
403. Lee WM, Jalan RV. Treatment of hyperammonemia in liver failure: A tale of two enzymes. *Gastroenterology* 2009;136:2048-51.
404. Lee WM, Larson AM, Arenas J. Thinking through acetaminophen toxicity and transplantation: choosing worthy recipients. *Liver Transpl* 2009;15:567-569.
405. Lee WM. Point-counterpoint: The case for limiting acetaminophen-related deaths: Smaller doses and unbundling the opioid-acetaminophen compounds. *Clin Pharm Therap* 2010;88:289-92.
406. Lee WM. Commentary: Persistently increased acetaminophen concentrations in a patient with acute liver failure. *Clin Chem* 2011;57:12-13.
407. Yuan HJ, Lee WM. Editorial: Update of Chronic Hepatitis B. *Current Opinion in Gastroenterology* 2011;27:217-23.

408. Tujios S, Lee WM. Acute Liver Failure in Sherlock's Diseases of the Liver and Biliary System, 12th edition, edited by Dooley J, Burroughs A, Heathcote J and Lok ASF. London, 2011.
409. Lee WM. Drug-induced liver disease. In Yamada Textbook of Gastroenterology and Hepatology, Sixth Edition, Philadelphia, PA, In press, 2011.
410. Hanje AJ, Michaels A, Lee WM. Is *N*-acetylcysteine Effective in All Non-acetaminophen Acute Liver Failure. In Controversies in Hepatology. Donald M. Jensen, Editor. Slack Incorporated, Philadelphia, 2011.
411. Lee WM. Toxin- and Drug-Induced Liver Disease. In Cecil's Textbook of Medicine, 24th Edition, Lee Goldman, Editor, 2011, p.
412. Lee WM. Determining prognosis in acute liver failure. Nat Rev Gastroenterol Hepatol 2012;9:192-4.
413. Lee WM. Acute Liver Failure. Semin Respir Crit Care Med. 2012;33:36-45.
414. Tujios SR, Lee WM. New advances in chronic hepatitis B. Curr Opin Gastroenterol 2012;28:193-97.
415. Casey LC, Lee WM. Hepatitis C therapy update. Curr Opin Gastroenterol 2012;28:188-92.
416. Lee WM. Recent developments in acute liver failure. Clin Gastroenterol 2012; 26:3-16.
417. Almadani B, Sood N, Yearsley M, Lee WM. Life threatening variceal hemorrhage in a woman with severe pulmonary arterial hypertension. Gastroenterol and Hepatol 2012;8:404-408.
418. Lee WM. Acute liver failure. Semin Respir Crit Care Med 2012;33:36-45.
419. Lee WM. Liver: determining prognosis in acute liver failure. Nat Rev Gastroenterol Hepatol 2012;9:192-4.
420. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure. Hepatology 2012;55:965-7.
421. Casey LC, Lee WM. Hepatitis C therapy update 2013. Curr Opin Gastroenterol. 2013;29:243-9.

422. Tujios SR, Lee WM. Update in the management of chronic hepatitis B. *Curr Opin Gastroenterol* 2013;29:250-6.
423. Tran Thanh, Lee WM. DILI: New insights into diagnosis and management. *Curr Hep Rep* 2013: epub ahead of print.
424. Lee WM. Drug-induced liver injury. *Clin Liver Dis* 2013;17;575–586.
425. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. *Am J Gastroenterol* 2014;109:950-66
426. Apica BS and Lee WM. Drug-Induced Liver Injury. In: Linda M. McManus, Richard N. Mitchell, editors. *Pathobiology of Human Disease*. San Diego: Elsevier; 2014. p. 1825-1837.
427. Bernal W, Lee WM, Wendon J, Larsen FS, Williams R. Acute liver failure: A curable disease by 2024? *J Hepatol* 2015;62(1 Suppl):S112-20.
428. Lee WM and Dienstag J. Toxic and Drug-Induced Hepatitis. In: Kasper DL, Fauci A, Hauser SL, Longo DL, Jameson JL, Loscalzo J. *Harrison's 19th Edition, Principles of Internal Medicine*, McGraw Hill, New York: 2015; p. 2023-30.
429. Lee WM. Toxic and Drug-Induced Liver Disease. In: Goldman L and Schafer AI. *Goldman-Cecil Medicine, 25th Edition*, 2015, Elsevier, Philadelphia PA, p. 1006-1010.
430. Lee WM. Drug-Induced Liver Disease. Chapter 97, pp 1958-72. In: Podolsky D, et al. *Yamada's Textbook of Gastroenterology, 6th Edition*, 2015; Hoboken, NJ.
431. Lee WM. Acute Liver Failure. Chapter 98, pp 1973-88. In: Podolsky D, et al. *Yamada's Textbook of Gastroenterology, 6th Edition*, 2015; Hoboken, NJ.
409. Lee WM. Public Health: Acetaminophen (APAP) hepatotoxicity—Isn't it time for APAP to go away? *J Hepatol* 2017;67:1324-31.
410. Lee WM and Dienstag J. Toxic and Drug-Induced Hepatitis. In: Kasper DL, Fauci A, Hauser SL, Longo DL, Jameson JL, Loscalzo J. *Harrison's 20th Edition, Principles of Internal Medicine*, McGraw Hill, New York: 2018; p. 2023-30.
411. Tujios SR, Lee WM. Acute liver failure. In: Dooley JS, Lok ASF, Garcia-Tsao G, Pinzani M. *Sherlock's Diseases of the Liver and Biliary System*. Wiley Blackwell, Oxford UK. 2018; 62-81.
412. Tran T, Lee WM. Drug-Induced Liver Disease in *Scientific American Gastroenterology, Hepatology, and Endoscopy*, electronic book. New York 2016.

413. Tran T, Burrell M, Lee WM. Hepatic arterio-portal fistulae: Two case reports and a review of the literature. *Clin Med Rev Case Rep* 2015;2:3.
414. Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. *Liver Int* 2018;38:6-14.
415. Mayberry J, Lee WM. The revolution in treatment of hepatitis C. *Med Clin N Am* 2019;108:43-55.
416. Rich NE, Lee WM. Editorial: Liver test abnormalities in oncology patients in the age of the checkpoint inhibitors. *Aliment Pharmacol Ther* 2019;50:831-832.
417. Chandramouli S, Lee WM, Lo J, Toomay S, Tujios S. Prophylactic transjugular intra-hepatic portosystemic shunt placement for cirrhosis management in pregnancy. *Hepatology* 2019: Dec 21 epub ahead of print.
418. Lee WM. Toxic and Drug-Induced Liver Disease. In: Goldman L and Schafer AI. *Goldman-Cecil Medicine*, 26th Edition, 2019, Elsevier, Philadelphia PA, p. 1006-1010.
419. Pedersen MR, Fontana RJ, Lee WM. Electronic image of the month: Palmar xanthomata in a resolving cholestatic liver injury. *Am J Gastroenterol* 2020; online ahead of print.
420. James LP, McGill MR, Roberts DW, Hinson JA, Lee WM. Advances in biomarker development in acetaminophen toxicity. *Adv Clin Chem* 2020;98:35-50.
421. Knooihuisen SAI, Aday A, Lee WM. Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19. *Hepatology* 2020; epub ahead of print..